Filing Details

Accession Number:
0001209191-20-024151
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-10 17:17:15
Reporting Period:
2020-04-08
Accepted Time:
2020-04-10 17:17:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1532346 Atreca Inc. BCEL Pharmaceutical Preparations (2834) 273723255
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1773750 Michael Norman Greenberg C/O Atreca, Inc., 450 East Jamie Court
South San Francisco CA 94080
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2020-04-08 8,000 $4.56 8,000 No 4 M Direct
Class A Common Stock Disposition 2020-04-08 8,000 $15.01 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Stock Option (right to buy) Disposition 2020-04-08 8,000 $0.00 8,000 $4.56
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
67,201 2026-05-09 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2019.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.06, inclusive. The reporting person undertakes to provide to Atreca, Inc., any security holder of Atreca, Inc., or the staff of the Securities and Exchange Commission, upon request,full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
  3. 1/4 of the Option vested on 5/2/2017 and 1/48 of the Option vests in equal monthly installments as measured from 5/2/2017. The shares subject to this option are early exercisable, subject to the Issuer's right to repurchase. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.